Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma
Status:
Terminated
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the combination of Revlimid® (lenalidomide) and
Nexavar® (sorafenib) for the treatment of hepatocellular carcinoma that can't be cured with
surgery.